Breast Cancer Care (BCC) has launched a virtual tool on Amazon’s Alexa which shares information on the signs and symptoms of breast cancer | via Digital Health
The tool can help guide women through a breast check and highlight the eight most common signs and symptoms of breast cancer to look out for.
Addie Mitchell, clinical nurse specialist at BCC, told Digital Health News that she hoped the digital tool would help give women more confidence to check for breast cancer. She said: “It gives them the confidence and assurance of being able to check in their own home. Checking for symptoms of breast cancer can cause a lot of anxiety as they don’t know what to look for, but the Alexa tool can help by listing the eight common ones.”
Mitchell added that the Alexa tool will also prompt users who may think they have one or more of the symptoms to get it checked out by their GP.
Information for local providers and commissioners on leading NHS breast screening services | Public Health England
This guidance sets out the principles for the organisation and leadership of local breast screening services. The guidance is aimed at those who are responsible for making sure breast screening services are managed in a professional and effective way. This involves meeting agreed standards and continually striving to improve performance.
More women attend for breast screening thanks to success of digital inclusion project | NHS Digital
An NHS project using social media to improve health by boosting digital inclusion has led to a 13 per cent increase in first time attendances for breast screening in Stoke-on-Trent over four years.
The local initiative saw information about screening posted on Facebook community groups, which empowered and enabled women to make appointments by reducing their anxiety around breast examinations. It also allowed them to communicate quickly and easily with health practitioners to ask questions about the screening process.
Through this project, the North Midlands Breast Screening Service promoted their Facebook page on local community groups which their target group – women aged over 50 – regularly visited.
The screening team posted information such as patients explaining about how the screening process works and how it has affected them, and videos showing the rooms where it takes place. Posts were designed to encourage women to share them and so spread the message about the benefits and importance of screening.
The service’s Facebook page also answered questions in the group and by direct messaging, enabling women to book appointments more easily.
A case study showing how cancer survivors in Salisbury feel more confident and less fatigued after enhanced support to live better after cancer | via NHS England
A new breast cancer stratified follow-up pathway, to increase the support given to breast cancer survivors, was rolled out at Salisbury Hospital in 2016.
The pathway includes a Holistic Needs Assessment (HNA) followed by a two-hour Moving Forward group. Hosted by a Consultant and a nurse, it addresses immediate health and wellbeing concerns. Offered to everyone on the patient initiated follow up, the average rating on session usefulness is 4.45 out of five. The average self-reported confidence score is 4.65. However the support does not stop there, patients identified as requiring more support are referred to the Cancer wellbeing group.
This group meets once a week for seven weeks. Hosted by a Clinical Psychologist and Gym Instructor qualified in rehabilitation, each two hour session starts with wellbeing advice, such as finance and benefits, diet or mindfulness and ends with a suitable rehabilitation exercise session. Group members unable to participate in group exercise receive a personal rehabilitation exercise programme. Members can also access weekly swimming sessions in the hospital pool. The average satisfaction rating for the group is 4.5 out of five, while on average, members report fatigue on daily life scores reduced by one third.
NHS England | August 2018 |Breast cancer survivors control their follow-up care in Maidstone
A new case study from NHS England highlights how patients with breast cancer in are able to control their own care in Maidstone, Kent. The Open Access programme enables patients to have access to regular mammograms, support advice and appropriate clinical follow up up to five years following treatment for breast cancer. The programme recognises patients as individuals and that the way in which they want to be supported may change during their recovery, the team introduced an Open Access Programme, based upon a successful model in place at the Royal Marsden Hospital.
A reduction of 3,000 breast outpatient appointments
Patients access suitable clinical appointments and contact their nurse appropriately.
Timely referral to an appropriate clinician (ie surgeon, oncologist, nurse)
Appointments aligned to patient need or want
Fast access to the Cancer Nurse to answer questions and concerns.
HQIP | June 2018 | National Audit of Breast Cancer in Older Patients: 2018 Annual Report
Health Quality Improvement Programme (HQIP) has produced a report which presents information on the care received by women diagnosed between 1 January 2014 and 31 December 2016 in England and Wales. As well as describing how these patterns of care differ between women in the younger and older age groups, the report also distinguishes between three main groups of breast cancer – women with ductal carcinoma in situ, with early invasive disease , and with advanced disease.
The report is primarily written for clinicians, providers of breast cancer services, commissioners and healthcare regulators. A version for patients and the general public will be available in summer 2018 (Source: HQIP).
University of Leeds |April 2018 |Women at increased cancer risk shun preventative tamoxifen therapy
A study published in Breast Cancer Research and Treatment shows that only 1 in 7 women who were offered Tamoxifen due to a familial history of cancer decided to take it. This new research sought to highlight that women eligible to take the drug were electing not to, it also aimed to explore the reasons behind such decisions. Researchers also found that patients consulted informal networks such as friends and family before making a decision about whether to take Tamoxifen (via University of Leeds) .
Whether the participants had children also had an impact on the decision, the scientists found those with children were more likely to take the drug. One participant explained that taking the drug might affect her ability to care for her children and parents, so decided not to take it.
The study was conducted in collaboration with scientists at the University Hospitals Southampton, University College London, Queen Mary University, University of Leeds and Northwestern University. The research was funded by Cancer Research UK and Yorkshire Cancer Research.
Purpose Uptake of preventive therapy for women at increased breast cancer risk in England is unknown following the introduction of UK clinical guidelines in 2013. Preventive therapy could create socioeconomic inequalities in cancer incidence if it is more readily accepted by particular socio-demographic groups. In this multicentre study, we investigated uptake of tamoxifen and evaluated socio-demographic and clinical factors associated with initiation. We explored women’s experiences of treatment decision-making using qualitative interview data. Methods Between September 2015 and December 2016, women (n=732) attending an appointment at one of 20 centres in England to discuss breast cancer risk were approached to complete a survey containing socio-demographic details and nul-
liparity. Of the baseline survey respondents (n equal to 408/732, 55.7% response rate), self-reported uptake of tamoxifen at 3-month follow-up was reported in 258 (63.2%). Sixteen women participated in semi-structured interviews. Results One in seven (38/258=14.7%) women initiated tamoxifen. Women who had children were more likely to report use of tamoxifen than those without children (OR=5.26; 95%CI: 1.13–24.49, p=0.035). Interview data suggested that women weigh up risks and benefits of tamoxifen within the context of familial commitments, with exposure to significant other’s beliefs and experiences of cancer and medication a basis for their decision.
Conclusions Uptake of tamoxifen is low in clinical practice. There were no socio-demographic differences in uptake, suggesting that the introduction of breast cancer preventive therapy is unlikely to create socioeconomic inequalities in cancer incidence. Women’s decision-making was influenced by familial priorities, particularly having children.